Dividends & Buybacks ·
On June 15, 2026, Lakewood-Amedex Biotherapeutics Inc. filed a Certificate of Change in Nevada to effectuate a…
LABTLakewood-Amedex Biotherapeutics Inc.
On June 15, 2026, Lakewood-Amedex Biotherapeutics Inc. filed a Certificate of Change in Nevada to effectuate a 1-for-10 reverse stock split of its common stock. The split becomes effective at 4:01 p.m. ET on June 19, 2026, with split-adjusted trading on Nasdaq beginning June 22, 2026. This action reduces issued and outstanding shares from approximately 17,506,577 to 1,750,789 and reduces authorized shares to 12,500,000. Fractional shares will be rounded up to the next whole share. The company's ticker remains LABT, but a new CUSIP (51255A201) has been assigned. The company operates in the biotherapeutics industry, developing biological therapies.